Loading
Cancer Related Gene Regulation · Journal article
Genes Chromosomes and Cancer · August 1, 2026
Early or partial results. Treat as a signal, not a conclusion.
This in vitro study of MPNST cell lines and engineered human Schwann cells demonstrates that DNA hypomethylation alone, whether from PRC2 loss or DNA methyltransferase inhibitors, is insufficient to kill tumor cells in culture. The findings suggest differential mechanisms between two DNMTis (azacitidine showing direct cytotoxicity via RNA processing pathway upregulation; decitabine acting via immune microenvironment effects) but do not establish clinical efficacy or establish that combination therapy is superior in patients.
In vitro comparative mechanistic study using isogenic CRISPR-engineered cell lines. MPNST cell lines and isogenic CRISPR-engineered immortalized human Schwann cells with and without PRC2. Intervention: Decitabine and azacitidine (DNA methyltransferase inhibitors). Compared with: PRC2-proficient cells; untreated controls implied.
PRC2 loss results in upregulation of over 1200 genes due to global H3K27me3 depletion Decitabine and azacitidine have differential effects on MPNST cells despite both causing genome-wide hypomethylation Azacitidine exhibits direct tumor cell cytotoxicity and upregulates RNA processing genes; decitabine does not kill cells directly
Azacitidine exhibits direct tumor cell cytotoxicity and upregulates RNA processing genes; decitabine does not kill cells directly
The findings do not yet establish clinical recommendations. The suggestion for combination therapy with DNMTis is preliminary and requires in vivo and clinical validation before implementation in NF1-associated MPNST treatment.
In vitro mechanistic study in cell lines and engineered cells examining epigenetic mechanisms in MPNSTs; demonstrates proof-of-concept but lacks in vivo validation or clinical data.
As stated by the source record.
Quoted from the source exactly as published.
The findings do not yet establish clinical recommendations. The suggestion for combination therapy with DNMTis is preliminary and requires in vivo and clinical validation before implementation in NF1-associated MPNST treatment.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas and the most common cause of disease-associated death for neurofibromatosis type 1 (NF1) patients. In the context of NF1, MPNSTs develop from benign premalignant precursors and the transition to malignancy is typically accompanied by loss of the polycomb repressive complex 2 (PRC2), which results in aberrant upregulation of over 1200 genes due to global depletion of histone H3 lysine 27 trimethylation (H3K27me3). Previous studies suggest cells compensate for the loss of this repressive histone mark via hypermethylation of the genome. Here we analyzed genome-wide DNA methylation and the transcriptome in MPNST cell lines and isogenic PRC2-deficient and -proficient CRISPR-engineered immortalized human Schwann cells. In addition to effects of PRC2 status, we also measured the effects of two DNA methyltransferase inhibitors (DNMTi), decitabine and azacitidine. We found that PRC2 status does not affect global DNA methylation or average methylation levels across specific genomic features. Furthermore, decitabine and azacitidine have differential effects on MPNSTs. While both DNMTis hypomethylate the genome, they upregulate different targets. Azacitidine upregulates genes involved in RNA processing pathways and exhibits direct tumor cell cytotoxicity, while decitabine upregulates genes involved in the immune response, has no direct-cell killing effects, and likely suppresses tumor growth in vivo by altering the tumor microenvironment. We show that DNA hypomethylation alone is insufficient to kill MPNST cells, regardless of PRC2 status. Consequently, these findings suggest that DNMT inhibitors should be utilized in combination with other targeted therapies for MPNST patients.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.